Sellas arbitration claim against 3D Medicines dismissed, owes $1 million in legal fees
SLS•Arbitration loss and legal fees
Sellas lost a binding arbitration against 3D Medicines at the HKIAC, with the arbitrator dismissing its claims on July 24, 2026.
The arbitrator allocated about $1 million of 3D Medicines’ legal fees and costs to be paid by Sellas.
License agreement and future milestones
3D Medicines plans to keep developing and commercializing galinpepimut-S in Greater China under the exclusive license agreement.
Potential future milestone payments under the license totaled $191.5 million as of March 31, 2026, including a disputed $13 million milestone.
